CL2012002560A1 - Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7). - Google Patents

Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7).

Info

Publication number
CL2012002560A1
CL2012002560A1 CL2012002560A CL2012002560A CL2012002560A1 CL 2012002560 A1 CL2012002560 A1 CL 2012002560A1 CL 2012002560 A CL2012002560 A CL 2012002560A CL 2012002560 A CL2012002560 A CL 2012002560A CL 2012002560 A1 CL2012002560 A1 CL 2012002560A1
Authority
CL
Chile
Prior art keywords
nle3
peptide
amino acids
contiguous amino
hec
Prior art date
Application number
CL2012002560A
Other languages
English (en)
Inventor
Kathleen E Rodgers
Gere S Dizerega
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45571822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012002560(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Southern California filed Critical Univ Southern California
Publication of CL2012002560A1 publication Critical patent/CL2012002560A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Métodos para el tratamiento de úlceras de pie diabético que comprende un péptido de al menos 5 aminoácidos contiguos de NLE3 a(1-7) efectivo; formulación farmacéutica que comprende hidroxietil celulosa (HEC) y un péptido de al menos 5 aminoácidos contiguos de NLE3 A(1-7).
CL2012002560A 2011-02-02 2012-09-14 Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7). CL2012002560A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161438780P 2011-02-02 2011-02-02

Publications (1)

Publication Number Publication Date
CL2012002560A1 true CL2012002560A1 (es) 2013-03-22

Family

ID=45571822

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002560A CL2012002560A1 (es) 2011-02-02 2012-09-14 Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7).

Country Status (20)

Country Link
US (3) US8207233B1 (es)
EP (1) EP2536422B8 (es)
JP (2) JP5469777B2 (es)
KR (1) KR101514414B1 (es)
CN (1) CN102858360B (es)
AU (1) AU2012212220B2 (es)
BR (1) BR112013019513A2 (es)
CA (1) CA2793515C (es)
CL (1) CL2012002560A1 (es)
CO (1) CO6592101A2 (es)
DK (1) DK2536422T3 (es)
EA (1) EA026440B1 (es)
ES (1) ES2479765T3 (es)
MX (1) MX2012010783A (es)
PE (1) PE20130379A1 (es)
PL (1) PL2536422T3 (es)
PT (1) PT2536422E (es)
SG (1) SG183960A1 (es)
WO (1) WO2012106427A2 (es)
ZA (1) ZA201207340B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102858360B (zh) * 2011-02-02 2017-07-25 南加利福尼亚大学 治疗糖尿病足溃疡的方法
EP2849773A1 (en) 2012-05-14 2015-03-25 University of Southern California Methods for limiting development of a skin wound
CN104853749A (zh) * 2012-09-17 2015-08-19 塔瑞克斯制药有限公司 血管紧张素的口服制剂
US9289500B2 (en) * 2013-02-22 2016-03-22 The Regents Of The University Of California Saccharide-peptide hydrogels
KR102230461B1 (ko) 2013-03-15 2021-03-22 유니버시티 오브 써던 캘리포니아 엔지오텐신-관련 질환들의 치료를 위한 방법들, 화합물들 및 조성물들
EP2968441A1 (en) 2013-03-15 2016-01-20 University of Southern California Methods for treating multiple sclerosis
WO2015138288A1 (en) * 2014-03-10 2015-09-17 Rush University Medical Center Methods of promotion of healing of diabetic wounds
WO2016108130A1 (en) * 2014-12-30 2016-07-07 Sun Pharmaceutical Industries Limited Topical pharmaceutical compositions comprising nebivolol for the treatment of diabetic wounds
WO2017100276A1 (en) * 2015-12-08 2017-06-15 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers
WO2021072225A1 (en) * 2019-10-09 2021-04-15 Rush University Medical Center Modulating interleukin-10 signaling to boost healing in diabetic wounds

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015629A (en) 1989-06-26 1991-05-14 University Of Southern California Tissue repair
WO1993008825A1 (en) * 1991-11-04 1993-05-13 Zymogenetics, Inc. Pdgf gel formulation
ATE210677T1 (de) 1993-09-24 2001-12-15 Univ Southern California Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung
US5955430A (en) 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
EP1333034B1 (en) 1993-09-24 2010-07-14 University Of Southern California Use of angiotensin II analogs in tissue repair
US5834432A (en) 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
US6110895A (en) 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
US6335195B1 (en) 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
WO1998033813A2 (en) 1997-02-04 1998-08-06 University Of Southern California Method for accelerating healing of thermal injuries
US6248587B1 (en) 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
US6165978A (en) 1997-12-12 2000-12-26 University Of Southern California Wound healing composition
AU2593599A (en) 1998-02-09 1999-08-23 University Of Southern California Method of promoting keratinocyte proliferation
US6455500B1 (en) 1998-03-10 2002-09-24 University Of Southern California Radiation therapy methods
US7173011B2 (en) 2000-11-20 2007-02-06 University Of Southern California Radiation therapy methods
AU3077299A (en) 1998-03-11 1999-09-27 University Of Southern California Method of promoting production of living tissue equivalents
EP1073453B1 (en) 1998-05-11 2005-04-13 University Of Southern California Use of angiotensin analogs for the manufacture of a medicament for increasing white blood cell survival and mobilizing haematopoietic progenitor cells following chemotherapy
US6762167B1 (en) 1998-05-11 2004-07-13 University Of Southern California Methods for treating a patient undergoing chemotherapy
US6916783B2 (en) 1998-07-13 2005-07-12 University Of Southern California Methods for accelerating bone and cartilage growth and repair
ATE250423T1 (de) 1998-07-13 2003-10-15 Univ Southern California Verfahren zur beschleunigen den zuwachs und heilen von knochen und knorpel
JP2002522505A (ja) 1998-08-13 2002-07-23 ユニヴァースティ オブ サザーン カリフォルニア 虚血組織への血流を増加させる方法
US6730775B1 (en) 1999-03-23 2004-05-04 University Of Southern California Methods for limiting scar and adhesion formation
US7338938B2 (en) 1999-05-10 2008-03-04 University Of Southern California Methods for treating a patient undergoing chemotherapy
WO2001044270A2 (en) 1999-12-16 2001-06-21 University Of Southern California Methods for treating and preventing diabetic complications by use of angiotensin-related peptides
US6821953B1 (en) 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
AU2001218024A1 (en) * 2000-06-19 2002-01-02 University Of Southern California Methods for treating and preventing alopecia
US20060058238A1 (en) 2004-09-15 2006-03-16 Lee Laurent-Applegate Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
WO2009075881A2 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20090227507A1 (en) 2008-03-10 2009-09-10 University Of Southern California Angiotensin (1-7) Dosage Forms and Uses Thereof
US9272013B2 (en) 2010-03-26 2016-03-01 University Of Southern California Methods for treating combined radiation and thermal injury
EP2603228A1 (en) 2010-08-10 2013-06-19 The University Of Southern California Use of angiotensin- ii (1-7) in cell transplantation and as an agent for preventing/treating norovirus infection
CN102858360B (zh) * 2011-02-02 2017-07-25 南加利福尼亚大学 治疗糖尿病足溃疡的方法

Also Published As

Publication number Publication date
DK2536422T3 (da) 2014-07-28
BR112013019513A2 (pt) 2019-06-11
US8207233B1 (en) 2012-06-26
HK1180213A1 (en) 2013-10-18
PL2536422T3 (pl) 2014-09-30
AU2012212220B2 (en) 2013-04-04
KR20120137365A (ko) 2012-12-20
CO6592101A2 (es) 2013-01-02
EP2536422A2 (en) 2012-12-26
JP2013523781A (ja) 2013-06-17
WO2012106427A3 (en) 2012-09-20
PT2536422E (pt) 2014-07-18
AU2012212220A1 (en) 2012-10-18
US20120329729A1 (en) 2012-12-27
EP2536422B8 (en) 2023-06-21
MX2012010783A (es) 2012-11-23
ES2479765T3 (es) 2014-07-24
KR101514414B1 (ko) 2015-05-04
EP2536422B1 (en) 2014-04-30
CA2793515C (en) 2015-05-12
PE20130379A1 (es) 2013-04-13
US8207234B1 (en) 2012-06-26
CN102858360B (zh) 2017-07-25
WO2012106427A2 (en) 2012-08-09
EA026440B1 (ru) 2017-04-28
ZA201207340B (en) 2013-02-27
JP5469777B2 (ja) 2014-04-16
JP2014080425A (ja) 2014-05-08
US8536231B2 (en) 2013-09-17
CN102858360A (zh) 2013-01-02
CA2793515A1 (en) 2012-08-09
SG183960A1 (en) 2012-10-30
EA201201296A1 (ru) 2013-02-28

Similar Documents

Publication Publication Date Title
CL2012002560A1 (es) Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7).
CU20110153A7 (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
CL2014000630A1 (es) Una composicion que comprende 1) un compuesto derivado de nucleosido denominado como compuesto 10 y 2) un compuesto derivado de acido 5-tiofeno-2-carboxilico denominado como compuesto 5 o un compuesto derivado del ester metilico del acido carbamico denominado como compuesto 6; y su uso para el tratamiento profilactico o terapeutico de una infeccion por vhc.
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
MX366906B (es) Purificacion de iduronato-2-sulfatasa.
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
BR112013031268A8 (pt) polipeptídeos
PE20140255A1 (es) Tableta dispersable en forma oral
CL2015000289A1 (es) Compuesto citostatico derivado de niclosamida y compuesto alquilante derivado de 2,3,4,6,8-pentazabiciclo[4.3.0]nona-2,7-trieno; composicion farmaceutica que los comprende; y metodo para determinar si el tratamiento para un paciente con un tumor solido es adecuado.
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
BR112012017691A2 (pt) nova composição
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
CR20130181A (es) UNA COMPOSICIÓN QUE COMPRENDE 2-metilpropanotioato de S-[2-([[1-(2-etilbutil)ciclohexil]-carbonil]amino)fenilo] Y CROSCARMELOSA SODICA
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
NI201200196A (es) Agentes terapéuticos 976
ECSP13012765A (es) Combinación y composición para el tratamiento de obesidad
CO6751242A2 (es) Combinación y composición para el tratamiento de obesidad